liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: Results from the Swedish Irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) trial
Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden, Department of Internal Medicine, Uppsala University Hospital, SE-751 85 Uppsala, Sweden.
Melhus, H.åkan, Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden.
Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden.
Division of Internal Medicine, Karolinska Institute, Danderyd Hospital, Danderyd, Sweden.
Show others and affiliations
2002 (English)In: American Journal of Hypertension, ISSN 0895-7061, E-ISSN 1941-7225, Vol. 15, no 5, 389-393 p.Article in journal (Refereed) Published
Abstract [en]

Background: Our aim was to determine whether the aldosterone synthase (CYP11B2) -344 C/T polymorphism was associated with the blood pressure (BP)-lowering response to antihypertensive treatment. Methods: Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the ß1-adrenergic receptor blocker atenolol (n = 43). The aldosterone synthase (CYP11B2) -344 C/T polymorphism was analyzed using solid-phase minisequencing and related to BP reduction after 3 months treatment. Serum aldosterone levels were measured. Results: After 3 months treatment the mean reductions in BP were similar for both treatment groups. When assessing the systolic BP reduction in the irbesartan group, patients with the TT variant had a more pronounced reduction (-21 ± 19 SD mm Hg, n = 17) than both the TC (-14 ± 18 mm Hg, n = 18) and CC (0 ± 17 mm Hg, n = 8) genotypes (P = .04). There was no association between this polymorphism and the diastolic BP response. The -344 C/T polymorphism was not associated with the BP response to atenolol. Nor was it related to the baseline serum aldosterone level. Conclusions: The aldosterone synthase -344 C/T polymorphism was related to the BP-lowering response in hypertensive patients treated with the AT1-receptor antagonist irbesartan. © 2002 American Journal of Hypertension, Ltd.

Place, publisher, year, edition, pages
2002. Vol. 15, no 5, 389-393 p.
Keyword [en]
Aldosterone synthase, CYP11B2, Genetics, Hypertension, Treatment
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-47005DOI: 10.1016/S0895-7061(02)02256-2OAI: oai:DiVA.org:liu-47005DiVA: diva2:267901
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2017-12-13

Open Access in DiVA

No full text

Other links

Publisher's full text

Authority records BETA

Nyström, Fredrik

Search in DiVA

By author/editor
Nyström, Fredrik
By organisation
Clinical PharmacologyFaculty of Health SciencesInternal Medicine Department of Endocrinology and Gastroenterology UHL
In the same journal
American Journal of Hypertension
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 100 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf